UTHEALTH HOME ABOUT SBMI A-Z WEBMAIL INSIDE THE UNIVERSITY |
![]() |
|||||||
|
Fusion Protein:BRAF-AKAP9 |
Fusion Protein Summary |
![]() |
Fusion partner gene information | Fusion gene name: BRAF-AKAP9 | FusionPDB ID: 10112 | FusionGDB2.0 ID: 10112 | Hgene | Tgene | Gene symbol | BRAF | AKAP9 | Gene ID | 673 | 10142 |
Gene name | B-Raf proto-oncogene, serine/threonine kinase | A-kinase anchoring protein 9 | |
Synonyms | B-RAF1|B-raf|BRAF1|NS7|RAFB1 | AKAP-9|AKAP350|AKAP450|CG-NAP|HYPERION|LQT11|MU-RMS-40.16A|PPP1R45|PRKA9|YOTIAO | |
Cytomap | 7q34 | 7q21.2 | |
Type of gene | protein-coding | protein-coding | |
Description | serine/threonine-protein kinase B-raf94 kDa B-raf proteinB-Raf proto-oncogene serine/threonine-protein kinase (p94)B-Raf serine/threonine-proteinmurine sarcoma viral (v-raf) oncogene homolog B1proto-oncogene B-Rafv-raf murine sarcoma viral oncogene | A-kinase anchor protein 9A kinase (PRKA) anchor protein (yotiao) 9A kinase (PRKA) anchor protein 9A-kinase anchor protein 350 kDaA-kinase anchor protein 450 kDaAKAP 120-like proteinAKAP9-BRAF fusion proteincentrosome- and Golgi-localized PKN-associ | |
Modification date | 20200329 | 20200328 | |
UniProtAcc | P15056 | Q99996 | |
Ensembl transtripts involved in fusion gene | ENST ids | ENST00000288602, | ENST00000394564, ENST00000491695, ENST00000356239, ENST00000358100, ENST00000359028, |
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0) | * DoF score | 28 X 21 X 11=6468 | 11 X 17 X 7=1309 |
# samples | 32 | 15 | |
** MAII score | log2(32/6468*10)=-4.3371758685863 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | log2(15/1309*10)=-3.12543069144936 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | |
Context (manual curation of fusion genes in FusionPDB) | PubMed: BRAF [Title/Abstract] AND AKAP9 [Title/Abstract] AND fusion [Title/Abstract] | ||
Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0) | AKAP9(91632550)-BRAF(140434354), # samples:1 AKAP9(91632550)-BRAF(140487386), # samples:1 AKAP9(91739875)-BRAF(140513187), # samples:1 | ||
Anticipated loss of major functional domain due to fusion event. | AKAP9-BRAF seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. AKAP9-BRAF seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF. |
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
![]() |
Partner | Gene | GO ID | GO term | PubMed ID |
Hgene | BRAF | GO:0000186 | activation of MAPKK activity | 29433126 |
Hgene | BRAF | GO:0006468 | protein phosphorylation | 17563371 |
Hgene | BRAF | GO:0010828 | positive regulation of glucose transmembrane transport | 23010278 |
Hgene | BRAF | GO:0033138 | positive regulation of peptidyl-serine phosphorylation | 19667065 |
Hgene | BRAF | GO:0043066 | negative regulation of apoptotic process | 19667065 |
Hgene | BRAF | GO:0070374 | positive regulation of ERK1 and ERK2 cascade | 22065586 |
Hgene | BRAF | GO:0071277 | cellular response to calcium ion | 18567582 |
Hgene | BRAF | GO:0090150 | establishment of protein localization to membrane | 23010278 |
Tgene | AKAP9 | GO:0098962 | regulation of postsynaptic neurotransmitter receptor activity | 10390370 |
Tgene | AKAP9 | GO:1903358 | regulation of Golgi organization | 27666745 |
![]() * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
![]() * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
Top |
Fusion Gene Sample Information |
![]() |
![]() * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
Source | Disease | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
ChimerKB3 | . | . | BRAF | chr7 | 140494107 | - | AKAP9 | chr7 | 91641742 | + |
Top |
Fusion ORF Analysis |
![]() |
Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | Seq length (transcript) | BP loci (transcript) | Predicted start (transcript) | Predicted stop (transcript) | Seq length (amino acids) |
ENST00000288602 | BRAF | chr7 | 140494107 | - | ENST00000356239 | AKAP9 | chr7 | 91641742 | + | 10121 | 1201 | 61 | 9606 | 3181 |
ENST00000288602 | BRAF | chr7 | 140494107 | - | ENST00000358100 | AKAP9 | chr7 | 91641742 | + | 9935 | 1201 | 61 | 9420 | 3119 |
ENST00000288602 | BRAF | chr7 | 140494107 | - | ENST00000359028 | AKAP9 | chr7 | 91641742 | + | 10097 | 1201 | 61 | 9582 | 3173 |
![]() |
Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | No-coding score | Coding score |
Top |
Fusion Amino Acid Sequences |
![]() |
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP >10112_10112_1_BRAF-AKAP9_BRAF_chr7_140494107_ENST00000288602_AKAP9_chr7_91641742_ENST00000356239_length(amino acids)=3181AA_BP=380 MAALSGGGGGGAEPGQALFNGDMEPEAGAGAGAAASSAADPAIPEEVWNIKQMIKLTQEHIEALLDKFGGEHNPPSIYLEAYEEYTSKLD ALQQREQQLLESLGNGTDFSVSSSASMDTVTSSSSSSLSVLPSSLSVFQNPTDVARSNPKSPQKPIVRVFLPNKQRTVVPARCGVTVRDS LKKALMMRGLIPECCAVYRIQDGEKKPIGWDTDISWLTGEELHVEVLENVPLTTHNFVRKTFFTLAFCDFCRKLLFQGFRCQTCGYKFHQ RCSTEVPLMCVNYDQLDLLFVSKFFEHHPIPQEEASLAETALTSGSSPSAPASDSIGPQILTSPSPSKSIPIPQPFRPADEDHRNQFGQR DRSSSAPNVHINTIEPVNIDNDLRLQMEAQRICLSLVYSTHVDQVREYMENEKDKALCSLKEELIFAQEEKIKELQKIHQLELQTMKTQE TGDEGKPLHLLIGKLQKAVSEECSYFLQTLCSVLGEYYTPALKCEVNAEDKENSGDYISENEDPELQDYRYEVQDFQENMHTLLNKVTEE YNKLLVLQTRLSKIWGQQTDGMKLEFGEENLPKEETEFLSIHSQMTNLEDIDVNHKSKLSSLQDLEKTKLEEQVQELESLISSLQQQLKE TEQNYEAEIHCLQKRLQAVSESTVPPSLPVDSVVITESDAQRTMYPGSCVKKNIDGTIEFSGEFGVKEETNIVKLLEKQYQEQLEEEVAK VIVSMSIAFAQQTELSRISGGKENTASSKQAHAVCQQEQHYFNEMKLSQDQIGFQTFETVDVKFKEEFKPLSKELGEHGKEILLSNSDPH DIPESKDCVLTISEEMFSKDKTFIVRQSIHDEISVSSMDASRQLMLNEEQLEDMRQELVRQYQEHQQATELLRQAHMRQMERQREDQEQL QEEIKRLNRQLAQRSSIDNENLVSERERVLLEELEALKQLSLAGREKLCCELRNSSTQTQNGNENQGEVEEQTFKEKELDRKPEDVPPEI LSNERYALQKANNRLLKILLEVVKTTAAVEETIGRHVLGILDRSSKSQSSASLIWRSEAEASVKSCVHEEHTRVTDESIPSYSGSDMPRN DINMWSKVTEEGTELSQRLVRSGFAGTEIDPENEELMLNISSRLQAAVEKLLEAISETSSQLEHAKVTQTELMRESFRQKQEATESLKCQ EELRERLHEESRAREQLAVELSKAEGVIDGYADEKTLFERQIQEKTDIIDRLEQELLCASNRLQELEAEQQQIQEERELLSRQKEAMKAE AGPVEQQLLQETEKLMKEKLEVQCQAEKVRDDLQKQVKALEIDVEEQVSRFIELEQEKNTELMDLRQQNQALEKQLEKMRKFLDEQAIDR EHERDVFQQEIQKLEQQLKVVPRFQPISEHQTREVEQLANHLKEKTDKCSELLLSKEQLQRDIQERNEEIEKLEFRVRELEQALLVSADT FQKVEDRKHFGAVEAKPELSLEVQLQAERDAIDRKEKEITNLEEQLEQFREELENKNEEVQQLHMQLEIQKKESTTRLQELEQENKLFKD DMEKLGLAIKESDAMSTQDQHVLFGKFAQIIQEKEVEIDQLNEQVTKLQQQLKITTDNKVIEEKNELIRDLETQIECLMSDQECVKRNRE EEIEQLNEVIEKLQQELANIGQKTSMNAHSLSEEADSLKHQLDVVIAEKLALEQQVETANEEMTFMKNVLKETNFKMNQLTQELFSLKRE RESVEKIQSIPENSVNVAIDHLSKDKPELEVVLTEDALKSLENQTYFKSFEENGKGSIINLETRLLQLESTVSAKDLELTQCYKQIKDMQ EQGQFETEMLQKKIVNLQKIVEEKVAAALVSQIQLEAVQEYAKFCQDNQTISSEPERTNIQNLNQLREDELGSDISALTLRISELESQVV EMHTSLILEKEQVEIAEKNVLEKEKKLLELQKLLEGNEKKQREKEKKRSPQDVEVLKTTTELFHSNEESGFFNELEALRAESVATKAELA SYKEKAEKLQEELLVKETNMTSLQKDLSQVRDHLAEAKEKLSILEKEDETEVQESKKACMFEPLPIKLSKSIASQTDGTLKISSSNQTPQ ILVKNAGIQINLQSECSSEEVTEIISQFTEKIEKMQELHAAEILDMESRHISETETLKREHYVAVQLLKEECGTLKAVIQCLRSKEGSSI PELAHSDAYQTREICSSDSGSDWGQGIYLTHSQGFDIASEGRGEESESATDSFPKKIKGLLRAVHNEGMQVLSLTESPYSDGEDHSIQQV SEPWLEERKAYINTISSLKDLITKMQLQREAEVYDSSQSHESFSDWRGELLLALQQVFLEERSVLLAAFRTELTALGTTDAVGLLNCLEQ RIQEQGVEYQAAMECLQKADRRSLLSEIQALHAQMNGRKITLKREQESEKPSQELLEYNIQQKQSQMLEMQVELSSMKDRATELQEQLSS EKMVVAELKSELAQTKLELETTLKAQHKHLKELEAFRLEVKDKTDEVHLLNDTLASEQKKSRELQWALEKEKAKLGRSEERDKEELEDLK FSLESQKQRNLQLNLLLEQQKQLLNESQQKIESQRMLYDAQLSEEQGRNLELQVLLESEKVRIREMSSTLDRERELHAQLQSSDGTGQSR PPLPSEDLLKELQKQLEEKHSRIVELLNETEKYKLDSLQTRQQMEKDRQVHRKTLQTEQEANTEGQKKMHELQSKVEDLQRQLEEKRQQV YKLDLEGQRLQGIMQEFQKQELEREEKRESRRILYQNLNEPTTWSLTSDRTRNWVLQQKIEGETKESNYAKLIEMNGGGTGCNHELEMIR QKLQCVASKLQVLPQKASERLQFETADDEDFIWVQENIDEIILQLQKLTGQQGEEPSLVSPSTSCGSLTERLLRQNAELTGHISQLTEEK NDLRNMVMKLEEQIRWYRQTGAGRDNSSRFSLNGGANIEAIIASEKEVWNREKLTLQKSLKRAEAEVYKLKAELRNDSLLQTLSPDSEHV TLKRIYGKYLRAESFRKALIYQKKYLLLLLGGFQECEDATLALLARMGGQPAFTDLEVITNRPKGFTRFRSAVRVSIAISRMKFLVRRWH RVTGSVSININRDGFGLNQGAEKTDSFYHSSGGLELYGEPRHTTYRSRSDLDYIRSPLPFQNRYPGTPADFNPGSLACSQLQNYDPDRAL -------------------------------------------------------------- >10112_10112_2_BRAF-AKAP9_BRAF_chr7_140494107_ENST00000288602_AKAP9_chr7_91641742_ENST00000358100_length(amino acids)=3119AA_BP=380 MAALSGGGGGGAEPGQALFNGDMEPEAGAGAGAAASSAADPAIPEEVWNIKQMIKLTQEHIEALLDKFGGEHNPPSIYLEAYEEYTSKLD ALQQREQQLLESLGNGTDFSVSSSASMDTVTSSSSSSLSVLPSSLSVFQNPTDVARSNPKSPQKPIVRVFLPNKQRTVVPARCGVTVRDS LKKALMMRGLIPECCAVYRIQDGEKKPIGWDTDISWLTGEELHVEVLENVPLTTHNFVRKTFFTLAFCDFCRKLLFQGFRCQTCGYKFHQ RCSTEVPLMCVNYDQLDLLFVSKFFEHHPIPQEEASLAETALTSGSSPSAPASDSIGPQILTSPSPSKSIPIPQPFRPADEDHRNQFGQR DRSSSAPNVHINTIEPVNIDNDLRLQMEAQRICLSLVYSTHVDQVREYMENEKDKALCSLKEELIFAQEEKIKELQKIHQLELQTMKTQE TGDEGKPLHLLIGKLQKAVSEECSYFLQTLCSVLGEYYTPALKCEVNAEDKENSGDYISENEDPELQDYRYEVQDFQENMHTLLNKVTEE YNKLLVLQTRLSKIWGQQTDGMKLEFGEENLPKEETEFLSIHSQMTNLEDIDVNHKSKLSSLQDLEKTKLEEQVQELESLISSLQQQLKE TEQNYEAEIHCLQKRLQAVSESTVPPSLPVDSVVITESDAQRTMYPGSCVKKNIDGTIEFSGEFGVKEETNIVKLLEKQYQEQLEEEVAK VIVSMSIAFAQQTELSRISGGKENTASSKQAHAVCQQEQHYFNEMKLSQDQIGFQTFETVDVKFKEEFKPLSKELGEHGKEILLSNSDPH DIPESKDCVLTISEEMFSKDKTFIVRQSIHDEISVSSMDASRQLMLNEEQLEDMRQELVRQYQEHQQATELLRQAHMRQMERQREDQEQL QEEIKRLNRQLAQRSSIDNENLVSERERVLLEELEALKQLSLAGREKLCCELRNSSTQTQNGNENQGEVEEQTFKEKELDRKPEDVPPEI LSNERYALQKANNRLLKILLEVVKTTAAVEETIGRHVLGILDRSSKSQSSASLIWRSEAEASVKSCVHEEHTRVTDESIPSYSGSDMPRN DINMWSKVTEEGTELSQRLVRSGFAGTEIDPENEELMLNISSRLQAAVEKLLEAISETSSQLEHAKVTQTELMRESFRQKQEATESLKCQ EELRERLHEESRAREQLAVELSKAEGVIDGYADEKTLFERQIQEKTDIIDRLEQELLCASNRLQELEAEQQQIQEERELLSRQKEAMKAE AGPVEQQLLQETEKLMKEKLEVQCQAEKVRDDLQKQVKALEIDVEEQVSRFIELEQEKNTELMDLRQQNQALEKQLEKMRKFLDEQAIDR EHERDVFQQEIQKLEQQLKVVPRFQPISEHQTREVEQLANHLKEKTDKCSELLLSKEQLQRDIQERNEEIEKLEFRVRELEQALLVSADT FQKVEDRKHFGAVEAKPELSLEVQLQAERDAIDRKEKEITNLEEQLEQFREELENKNEEVQQLHMQLEIQKKESTTRLQELEQENKLFKD DMEKLGLAIKESDAMSTQDQHVLFGKFAQIIQEKEVEIDQLNEQVTKLQQQLKITTDNKVIEEKNELIRDLETQIECLMSDQECVKRNRE EEIEQLNEVIEKLQQELANIGQKTSMNAHSLSEEADSLKHQLDVVIAEKLALEQQVETANEEMTFMKNVLKETNFKMNQLTQELFSLKRE RESVEKIQSIPENSVNVAIDHLSKDKPELEVVLTEDALKSLENQTYFKSFEENGKGSIINLETRLLQLESTVSAKDLELTQCYKQIKDMQ EQGQFETEMLQKKIVNLQKIVEEKVAAALVSQIQLEAVQEYAKFCQDNQTISSEPERTNIQNLNQLREDELGSDISALTLRISELESQVV EMHTSLILEKEQVEIAEKNVLEKEKKLLELQKLLEGNEKKQREKEKKRSPQDVEVLKTTTELFHSNEESGFFNELEALRAESVATKAELA SYKEKAEKLQEELLVKETNMTSLQKDLSQVRDHLAEAKEKLSILEKEDETEVQESKKACMFEPLPIKLSKSIASQTDGTLKISSSNQTPQ ILVKNAGIQINLQSECSSEEVTEIISQFTEKIEKMQELHAAEILDMESRHISETETLKREHYVAVQLLKEECGTLKAVIQCLRSKEGLLR AVHNEGMQVLSLTESPYSDGEDHSIQQVSEPWLEERKAYINTISSLKDLITKMQLQREAEVYDSSQSHESFSDWRGELLLALQQVFLEER SVLLAAFRTELTALGTTDAVGLLNCLEQRIQEQGVEYQAAMECLQKADRRSLLSEIQALHAQMNGRKITLKREQESEKPSQELLEYNIQQ KQSQMLEMQVELSSMKDRATELQEQLSSEKMVVAELKSELAQTKLELETTLKAQHKHLKELEAFRLEVKDKTDEVHLLNDTLASEQKKSR ELQWALEKEKAKLGRSEERDKEELEDLKFSLESQKQRNLQLNLLLEQQKQLLNESQQKIESQRMLYDAQLSEEQGRNLELQVLLESEKVR IREMSSTLDRERELHAQLQSSDGTGQSRPPLPSEDLLKELQKQLEEKHSRIVELLNETEKYKLDSLQTRQQMEKDRQVHRKTLQTEQEAN TEGQKKMHELQSKVEDLQRQLEEKRQQVYKLDLEGQRLQGIMQEFQKQELEREEKRESRRILYQNLNEPTTWSLTSDRTRNWVLQQKIEG ETKESNYAKLIEMNGGGTGCNHELEMIRQKLQCVASKLQVLPQKASERLQFETADDEDFIWVQENIDEIILQLQKLTGQQGEEPSLVSPS TSCGSLTERLLRQNAELTGHISQLTEEKNDLRNMVMKLEEQIRWYRQTGAGRDNSSRFSLNGGANIEAIIASEKEVWNREKLTLQKSLKR AEAEVYKLKAELRNDSLLQTLSPDSEHVTLKRIYGKYLRAESFRKALIYQKKYLLLLLGGFQECEDATLALLARMGGQPAFTDLEVITNR PKGFTRFRSAVRVSIAISRMKFLVRRWHRVTGSVSININRDGFGLNQGAEKTDSFYHSSGGLELYGEPRHTTYRSRSDLDYIRSPLPFQN -------------------------------------------------------------- >10112_10112_3_BRAF-AKAP9_BRAF_chr7_140494107_ENST00000288602_AKAP9_chr7_91641742_ENST00000359028_length(amino acids)=3173AA_BP=380 MAALSGGGGGGAEPGQALFNGDMEPEAGAGAGAAASSAADPAIPEEVWNIKQMIKLTQEHIEALLDKFGGEHNPPSIYLEAYEEYTSKLD ALQQREQQLLESLGNGTDFSVSSSASMDTVTSSSSSSLSVLPSSLSVFQNPTDVARSNPKSPQKPIVRVFLPNKQRTVVPARCGVTVRDS LKKALMMRGLIPECCAVYRIQDGEKKPIGWDTDISWLTGEELHVEVLENVPLTTHNFVRKTFFTLAFCDFCRKLLFQGFRCQTCGYKFHQ RCSTEVPLMCVNYDQLDLLFVSKFFEHHPIPQEEASLAETALTSGSSPSAPASDSIGPQILTSPSPSKSIPIPQPFRPADEDHRNQFGQR DRSSSAPNVHINTIEPVNIDNDLRLQMEAQRICLSLVYSTHVDQVREYMENEKDKALCSLKEELIFAQEEKIKELQKIHQLELQTMKTQE TGDEGKPLHLLIGKLQKAVSEECSYFLQTLCSVLGEYYTPALKCEVNAEDKENSGDYISENEDPELQDYRYEVQDFQENMHTLLNKVTEE YNKLLVLQTRLSKIWGQQTDGMKLEFGEENLPKEETEFLSIHSQMTNLEDIDVNHKSKLSSLQDLEKTKLEEQVQELESLISSLQQQLKE TEQNYEAEIHCLQKRLQAVSESTVPPSLPVDSVVITESDAQRTMYPGSCVKKNIDGTIEFSGEFGVKEETNIVKLLEKQYQEQLEEEVAK VIVSMSIAFAQQTELSRISGGKENTASSKQAHAVCQQEQHYFNEMKLSQDQIGFQTFETVDVKFKEEFKPLSKELGEHGKEILLSNSDPH DIPESKDCVLTISEEMFSKDKTFIVRQSIHDEISVSSMDASRQLMLNEEQLEDMRQELVRQYQEHQQATELLRQAHMRQMERQREDQEQL QEEIKRLNRQLAQRSSIDNENLVSERERVLLEELEALKQLSLAGREKLCCELRNSSTQTQNGNENQGEVEEQTFKEKELDRKPEDVPPEI LSNERYALQKANNRLLKILLEVVKTTAAVEETIGRHVLGILDRSSKSQSSASLIWRSEAEASVKSCVHEEHTRVTDESIPSYSGSDMPRN DINMWSKVTEEGTELSQRLVRSGFAGTEIDPENEELMLNISSRLQAAVEKLLEAISETSSQLEHAKVTQTELMRESFRQKQEATESLKCQ EELRERLHEESRAREQLAVELSKAEGVIDGYADEKTLFERQIQEKTDIIDRLEQELLCASNRLQELEAEQQQIQEERELLSRQKEAMKAE AGPVEQQLLQETEKLMKEKLEVQCQAEKVRDDLQKQVKALEIDVEEQVSRFIELEQEKNTELMDLRQQNQALEKQLEKMRKFLDEQAIDR EHERDVFQQEIQKLEQQLKVVPRFQPISEHQTREVEQLANHLKEKTDKCSELLLSKEQLQRDIQERNEEIEKLEFRVRELEQALLVSADT FQKVEDRKHFGAVEAKPELSLEVQLQAERDAIDRKEKEITNLEEQLEQFREELENKNEEVQQLHMQLEIQKKESTTRLQELEQENKLFKD DMEKLGLAIKESDAMSTQDQHVLFGKFAQIIQEKEVEIDQLNEQVTKLQQQLKITTDNKVIEEKNELIRDLETQIECLMSDQECVKRNRE EEIEQLNEVIEKLQQELANIGQKTSMNAHSLSEEADSLKHQLDVVIAEKLALEQQVETANEEMTFMKNVLKETNFKMNQLTQELFSLKRE RESVEKIQSIPENSVNVAIDHLSKDKPELEVVLTEDALKSLENQTYFKSFEENGKGSIINLETRLLQLESTVSAKDLELTQCYKQIKDMQ EQGQFETEMLQKKIVNLQKIVEEKVAAALVSQIQLEAVQEYAKFCQDNQTISSEPERTNIQNLNQLREDELGSDISALTLRISELESQVV EMHTSLILEKEQVEIAEKNVLEKEKKLLELQKLLEGNEKKQREKEKKRSPQDVEVLKTTTELFHSNEESGFFNELEALRAESVATKAELA SYKEKAEKLQEELLVKETNMTSLQKDLSQVRDHLAEAKEKLSILEKEDETEVQESKKACMFEPLPIKLSKSIASQTDGTLKISSSNQTPQ ILVKNAGIQINLQSECSSEEVTEIISQFTEKIEKMQELHAAEILDMESRHISETETLKREHYVAVQLLKEECGTLKAVIQCLRSKEVFGF YNMCFSTLCDSGSDWGQGIYLTHSQGFDIASEGRGEESESATDSFPKKIKGLLRAVHNEGMQVLSLTESPYSDGEDHSIQQVSEPWLEER KAYINTISSLKDLITKMQLQREAEVYDSSQSHESFSDWRGELLLALQQVFLEERSVLLAAFRTELTALGTTDAVGLLNCLEQRIQEQGVE YQAAMECLQKADRRSLLSEIQALHAQMNGRKITLKREQESEKPSQELLEYNIQQKQSQMLEMQVELSSMKDRATELQEQLSSEKMVVAEL KSELAQTKLELETTLKAQHKHLKELEAFRLEVKDKTDEVHLLNDTLASEQKKSRELQWALEKEKAKLGRSEERDKEELEDLKFSLESQKQ RNLQLNLLLEQQKQLLNESQQKIESQRMLYDAQLSEEQGRNLELQVLLESEKVRIREMSSTLDRERELHAQLQSSDGTGQSRPPLPSEDL LKELQKQLEEKHSRIVELLNETEKYKLDSLQTRQQMEKDRQVHRKTLQTEQEANTEGQKKMHELQSKVEDLQRQLEEKRQQVYKLDLEGQ RLQGIMQEFQKQELEREEKRESRRILYQNLNEPTTWSLTSDRTRNWVLQQKIEGETKESNYAKLIEMNGGGTGCNHELEMIRQKLQCVAS KLQVLPQKASERLQFETADDEDFIWVQENIDEIILQLQKLTGQQGEEPSLVSPSTSCGSLTERLLRQNAELTGHISQLTEEKNDLRNMVM KLEEQIRWYRQTGAGRDNSSRFSLNGGANIEAIIASEKEVWNREKLTLQKSLKRAEAEVYKLKAELRNDSLLQTLSPDSEHVTLKRIYGK YLRAESFRKALIYQKKYLLLLLGGFQECEDATLALLARMGGQPAFTDLEVITNRPKGFTRFRSAVRVSIAISRMKFLVRRWHRVTGSVSI NINRDGFGLNQGAEKTDSFYHSSGGLELYGEPRHTTYRSRSDLDYIRSPLPFQNRYPGTPADFNPGSLACSQLQNYDPDRALTDYITRLE -------------------------------------------------------------- |
Top |
Fusion Protein Functional Features |
![]() Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr7:91632550/chr7:140434354) - FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels. - How to search 1. Put your fusion gene symbol. 2. Press the tab key until there will be shown the breakpoint information filled. 4. Go down and press 'Search' tab twice. 4. Go down to have the hyperlink of the search result. 5. Click the hyperlink. 6. See the FGviewer result for your fusion gene. |
![]() |
![]() |
Hgene | Tgene |
BRAF | AKAP9 |
FUNCTION: Protein kinase involved in the transduction of mitogenic signals from the cell membrane to the nucleus (Probable). Phosphorylates MAP2K1, and thereby activates the MAP kinase signal transduction pathway (PubMed:21441910, PubMed:29433126). May play a role in the postsynaptic responses of hippocampal neurons (PubMed:1508179). {ECO:0000269|PubMed:1508179, ECO:0000269|PubMed:21441910, ECO:0000269|PubMed:29433126, ECO:0000305}. | FUNCTION: Scaffolding protein that assembles several protein kinases and phosphatases on the centrosome and Golgi apparatus. Required to maintain the integrity of the Golgi apparatus (PubMed:10202149, PubMed:15047863). Required for microtubule nucleation at the cis-side of the Golgi apparatus (PubMed:15047863, PubMed:19242490). Required for association of the centrosomes with the poles of the bipolar mitotic spindle during metaphase (PubMed:25657325). In complex with PDE4DIP isoform 13/MMG8/SMYLE, recruits CAMSAP2 to the Golgi apparatus and tethers non-centrosomal minus-end microtubules to the Golgi, an important step for polarized cell movement (PubMed:27666745, PubMed:28814570). In complex with PDE4DIP isoform 13/MMG8/SMYLE, EB1/MAPRE1 and CDK5RAP2, contributes to microtubules nucleation and extension also from the centrosome to the cell periphery (PubMed:29162697). {ECO:0000269|PubMed:10202149, ECO:0000269|PubMed:15047863, ECO:0000269|PubMed:19242490, ECO:0000269|PubMed:25657325, ECO:0000269|PubMed:27666745, ECO:0000269|PubMed:28814570, ECO:0000269|PubMed:29162697}.; FUNCTION: [Isoform 4]: Associated with the N-methyl-D-aspartate receptor and is specifically found in the neuromuscular junction (NMJ) as well as in neuronal synapses, suggesting a role in the organization of postsynaptic specializations. {ECO:0000269|PubMed:9482789}. |
![]() |
- Retained protein feature among the 13 regional features. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
- Not-retained protein feature among the 13 regional features. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
Top |
Fusion Protein Structures |
![]() * Here we show the 3D structure of the fusion proteins using Mol*. AlphaFold produces a per-residue confidence score (pLDDT) between 0 and 100. Model confidence is shown from the pLDDT values per residue. pLDDT corresponds to the model’s prediction of its score on the local Distance Difference Test. It is a measure of local accuracy (from AlphfaFold website). To color code individual residues, we transformed individual PDB files into CIF format. |
Fusion protein PDB link (fusion AA seq ID in FusionPDB) | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | AA seq | Len(AA seq) |
PDB file (1251) >>>1251.pdbFusion protein BP residue: 380 CIF file (1251) >>>1251.cif | BRAF | chr7 | 140494107 | - | AKAP9 | chr7 | 91641742 | + | MAALSGGGGGGAEPGQALFNGDMEPEAGAGAGAAASSAADPAIPEEVWNI KQMIKLTQEHIEALLDKFGGEHNPPSIYLEAYEEYTSKLDALQQREQQLL ESLGNGTDFSVSSSASMDTVTSSSSSSLSVLPSSLSVFQNPTDVARSNPK SPQKPIVRVFLPNKQRTVVPARCGVTVRDSLKKALMMRGLIPECCAVYRI QDGEKKPIGWDTDISWLTGEELHVEVLENVPLTTHNFVRKTFFTLAFCDF CRKLLFQGFRCQTCGYKFHQRCSTEVPLMCVNYDQLDLLFVSKFFEHHPI PQEEASLAETALTSGSSPSAPASDSIGPQILTSPSPSKSIPIPQPFRPAD EDHRNQFGQRDRSSSAPNVHINTIEPVNIDNDLRLQMEAQRICLSLVYST HVDQVREYMENEKDKALCSLKEELIFAQEEKIKELQKIHQLELQTMKTQE TGDEGKPLHLLIGKLQKAVSEECSYFLQTLCSVLGEYYTPALKCEVNAED KENSGDYISENEDPELQDYRYEVQDFQENMHTLLNKVTEEYNKLLVLQTR LSKIWGQQTDGMKLEFGEENLPKEETEFLSIHSQMTNLEDIDVNHKSKLS SLQDLEKTKLEEQVQELESLISSLQQQLKETEQNYEAEIHCLQKRLQAVS ESTVPPSLPVDSVVITESDAQRTMYPGSCVKKNIDGTIEFSGEFGVKEET NIVKLLEKQYQEQLEEEVAKVIVSMSIAFAQQTELSRISGGKENTASSKQ AHAVCQQEQHYFNEMKLSQDQIGFQTFETVDVKFKEEFKPLSKELGEHGK EILLSNSDPHDIPESKDCVLTISEEMFSKDKTFIVRQSIHDEISVSSMDA SRQLMLNEEQLEDMRQELVRQYQEHQQATELLRQAHMRQMERQREDQEQL QEEIKRLNRQLAQRSSIDNENLVSERERVLLEELEALKQLSLAGREKLCC ELRNSSTQTQNGNENQGEVEEQTFKEKELDRKPEDVPPEILSNERYALQK ANNRLLKILLEVVKTTAAVEETIGRHVLGILDRSSKSQSSASLIWRSEAE ASVKSCVHEEHTRVTDESIPSYSGSDMPRNDINMWSKVTEEGTELSQRLV RSGFAGTEIDPENEELMLNISSRLQAAVEKLLEAISETSSQLEHAKVTQT ELMRESFRQKQEATESLKCQEELRERLHEESRAREQLAVELSKAEGVIDG YADEKTLFERQIQEKTDIIDRLEQELLCASNRLQELEAEQQQIQEERELL SRQKEAMKAEAGPVEQQLLQETEKLMKEKLEVQCQAEKVRDDLQKQVKAL EIDVEEQVSRFIELEQEKNTELMDLRQQNQALEKQLEKMRKFLDEQAIDR EHERDVFQQEIQKLEQQLKVVPRFQPISEHQTREVEQLANHLKEKTDKCS ELLLSKEQLQRDIQERNEEIEKLEFRVRELEQALLVSADTFQKVEDRKHF GAVEAKPELSLEVQLQAERDAIDRKEKEITNLEEQLEQFREELENKNEEV QQLHMQLEIQKKESTTRLQELEQENKLFKDDMEKLGLAIKESDAMSTQDQ HVLFGKFAQIIQEKEVEIDQLNEQVTKLQQQLKITTDNKVIEEKNELIRD LETQIECLMSDQECVKRNREEEIEQLNEVIEKLQQELANIGQKTSMNAHS LSEEADSLKHQLDVVIAEKLALEQQVETANEEMTFMKNVLKETNFKMNQL TQELFSLKRERESVEKIQSIPENSVNVAIDHLSKDKPELEVVLTEDALKS LENQTYFKSFEENGKGSIINLETRLLQLESTVSAKDLELTQCYKQIKDMQ EQGQFETEMLQKKIVNLQKIVEEKVAAALVSQIQLEAVQEYAKFCQDNQT ISSEPERTNIQNLNQLREDELGSDISALTLRISELESQVVEMHTSLILEK EQVEIAEKNVLEKEKKLLELQKLLEGNEKKQREKEKKRSPQDVEVLKTTT ELFHSNEESGFFNELEALRAESVATKAELASYKEKAEKLQEELLVKETNM TSLQKDLSQVRDHLAEAKEKLSILEKEDETEVQESKKACMFEPLPIKLSK SIASQTDGTLKISSSNQTPQILVKNAGIQINLQSECSSEEVTEIISQFTE KIEKMQELHAAEILDMESRHISETETLKREHYVAVQLLKEECGTLKAVIQ CLRSKEGLLRAVHNEGMQVLSLTESPYSDGEDHSIQQVSEPWLEERKAYI NTISSLKDLITKMQLQREAEVYDSSQSHESFSDWRGELLLALQQVFLEER SVLLAAFRTELTALGTTDAVGLLNCLEQRIQEQGVEYQAAMECLQKADRR SLLSEIQALHAQMNGRKITLKREQESEKPSQELLEYNIQQKQSQMLEMQV ELSSMKDRATELQEQLSSEKMVVAELKSELAQTKLELETTLKAQHKHLKE LEAFRLEVKDKTDEVHLLNDTLASEQKKSRELQWALEKEKAKLGRSEERD KEELEDLKFSLESQKQRNLQLNLLLEQQKQLLNESQQKIESQRMLYDAQL SEEQGRNLELQVLLESEKVRIREMSSTLDRERELHAQLQSSDGTGQSRPP LPSEDLLKELQKQLEEKHSRIVELLNETEKYKLDSLQTRQQMEKDRQVHR KTLQTEQEANTEGQKKMHELQSKVEDLQRQLEEKRQQVYKLDLEGQRLQG IMQEFQKQELEREEKRESRRILYQNLNEPTTWSLTSDRTRNWVLQQKIEG ETKESNYAKLIEMNGGGTGCNHELEMIRQKLQCVASKLQVLPQKASERLQ FETADDEDFIWVQENIDEIILQLQKLTGQQGEEPSLVSPSTSCGSLTERL LRQNAELTGHISQLTEEKNDLRNMVMKLEEQIRWYRQTGAGRDNSSRFSL NGGANIEAIIASEKEVWNREKLTLQKSLKRAEAEVYKLKAELRNDSLLQT LSPDSEHVTLKRIYGKYLRAESFRKALIYQKKYLLLLLGGFQECEDATLA LLARMGGQPAFTDLEVITNRPKGFTRFRSAVRVSIAISRMKFLVRRWHRV TGSVSININRDGFGLNQGAEKTDSFYHSSGGLELYGEPRHTTYRSRSDLD YIRSPLPFQNRYPGTPADFNPGSLACSQLQNYDPDRALTDYITRLEALQR | 3119 |
3D view using mol* of 1251 (AA BP:380) | ||||||||||
![]() | ||||||||||
PDB file (1254) >>>1254.pdbFusion protein BP residue: 380 CIF file (1254) >>>1254.cif | BRAF | chr7 | 140494107 | - | AKAP9 | chr7 | 91641742 | + | MAALSGGGGGGAEPGQALFNGDMEPEAGAGAGAAASSAADPAIPEEVWNI KQMIKLTQEHIEALLDKFGGEHNPPSIYLEAYEEYTSKLDALQQREQQLL ESLGNGTDFSVSSSASMDTVTSSSSSSLSVLPSSLSVFQNPTDVARSNPK SPQKPIVRVFLPNKQRTVVPARCGVTVRDSLKKALMMRGLIPECCAVYRI QDGEKKPIGWDTDISWLTGEELHVEVLENVPLTTHNFVRKTFFTLAFCDF CRKLLFQGFRCQTCGYKFHQRCSTEVPLMCVNYDQLDLLFVSKFFEHHPI PQEEASLAETALTSGSSPSAPASDSIGPQILTSPSPSKSIPIPQPFRPAD EDHRNQFGQRDRSSSAPNVHINTIEPVNIDNDLRLQMEAQRICLSLVYST HVDQVREYMENEKDKALCSLKEELIFAQEEKIKELQKIHQLELQTMKTQE TGDEGKPLHLLIGKLQKAVSEECSYFLQTLCSVLGEYYTPALKCEVNAED KENSGDYISENEDPELQDYRYEVQDFQENMHTLLNKVTEEYNKLLVLQTR LSKIWGQQTDGMKLEFGEENLPKEETEFLSIHSQMTNLEDIDVNHKSKLS SLQDLEKTKLEEQVQELESLISSLQQQLKETEQNYEAEIHCLQKRLQAVS ESTVPPSLPVDSVVITESDAQRTMYPGSCVKKNIDGTIEFSGEFGVKEET NIVKLLEKQYQEQLEEEVAKVIVSMSIAFAQQTELSRISGGKENTASSKQ AHAVCQQEQHYFNEMKLSQDQIGFQTFETVDVKFKEEFKPLSKELGEHGK EILLSNSDPHDIPESKDCVLTISEEMFSKDKTFIVRQSIHDEISVSSMDA SRQLMLNEEQLEDMRQELVRQYQEHQQATELLRQAHMRQMERQREDQEQL QEEIKRLNRQLAQRSSIDNENLVSERERVLLEELEALKQLSLAGREKLCC ELRNSSTQTQNGNENQGEVEEQTFKEKELDRKPEDVPPEILSNERYALQK ANNRLLKILLEVVKTTAAVEETIGRHVLGILDRSSKSQSSASLIWRSEAE ASVKSCVHEEHTRVTDESIPSYSGSDMPRNDINMWSKVTEEGTELSQRLV RSGFAGTEIDPENEELMLNISSRLQAAVEKLLEAISETSSQLEHAKVTQT ELMRESFRQKQEATESLKCQEELRERLHEESRAREQLAVELSKAEGVIDG YADEKTLFERQIQEKTDIIDRLEQELLCASNRLQELEAEQQQIQEERELL SRQKEAMKAEAGPVEQQLLQETEKLMKEKLEVQCQAEKVRDDLQKQVKAL EIDVEEQVSRFIELEQEKNTELMDLRQQNQALEKQLEKMRKFLDEQAIDR EHERDVFQQEIQKLEQQLKVVPRFQPISEHQTREVEQLANHLKEKTDKCS ELLLSKEQLQRDIQERNEEIEKLEFRVRELEQALLVSADTFQKVEDRKHF GAVEAKPELSLEVQLQAERDAIDRKEKEITNLEEQLEQFREELENKNEEV QQLHMQLEIQKKESTTRLQELEQENKLFKDDMEKLGLAIKESDAMSTQDQ HVLFGKFAQIIQEKEVEIDQLNEQVTKLQQQLKITTDNKVIEEKNELIRD LETQIECLMSDQECVKRNREEEIEQLNEVIEKLQQELANIGQKTSMNAHS LSEEADSLKHQLDVVIAEKLALEQQVETANEEMTFMKNVLKETNFKMNQL TQELFSLKRERESVEKIQSIPENSVNVAIDHLSKDKPELEVVLTEDALKS LENQTYFKSFEENGKGSIINLETRLLQLESTVSAKDLELTQCYKQIKDMQ EQGQFETEMLQKKIVNLQKIVEEKVAAALVSQIQLEAVQEYAKFCQDNQT ISSEPERTNIQNLNQLREDELGSDISALTLRISELESQVVEMHTSLILEK EQVEIAEKNVLEKEKKLLELQKLLEGNEKKQREKEKKRSPQDVEVLKTTT ELFHSNEESGFFNELEALRAESVATKAELASYKEKAEKLQEELLVKETNM TSLQKDLSQVRDHLAEAKEKLSILEKEDETEVQESKKACMFEPLPIKLSK SIASQTDGTLKISSSNQTPQILVKNAGIQINLQSECSSEEVTEIISQFTE KIEKMQELHAAEILDMESRHISETETLKREHYVAVQLLKEECGTLKAVIQ CLRSKEVFGFYNMCFSTLCDSGSDWGQGIYLTHSQGFDIASEGRGEESES ATDSFPKKIKGLLRAVHNEGMQVLSLTESPYSDGEDHSIQQVSEPWLEER KAYINTISSLKDLITKMQLQREAEVYDSSQSHESFSDWRGELLLALQQVF LEERSVLLAAFRTELTALGTTDAVGLLNCLEQRIQEQGVEYQAAMECLQK ADRRSLLSEIQALHAQMNGRKITLKREQESEKPSQELLEYNIQQKQSQML EMQVELSSMKDRATELQEQLSSEKMVVAELKSELAQTKLELETTLKAQHK HLKELEAFRLEVKDKTDEVHLLNDTLASEQKKSRELQWALEKEKAKLGRS EERDKEELEDLKFSLESQKQRNLQLNLLLEQQKQLLNESQQKIESQRMLY DAQLSEEQGRNLELQVLLESEKVRIREMSSTLDRERELHAQLQSSDGTGQ SRPPLPSEDLLKELQKQLEEKHSRIVELLNETEKYKLDSLQTRQQMEKDR QVHRKTLQTEQEANTEGQKKMHELQSKVEDLQRQLEEKRQQVYKLDLEGQ RLQGIMQEFQKQELEREEKRESRRILYQNLNEPTTWSLTSDRTRNWVLQQ KIEGETKESNYAKLIEMNGGGTGCNHELEMIRQKLQCVASKLQVLPQKAS ERLQFETADDEDFIWVQENIDEIILQLQKLTGQQGEEPSLVSPSTSCGSL TERLLRQNAELTGHISQLTEEKNDLRNMVMKLEEQIRWYRQTGAGRDNSS RFSLNGGANIEAIIASEKEVWNREKLTLQKSLKRAEAEVYKLKAELRNDS LLQTLSPDSEHVTLKRIYGKYLRAESFRKALIYQKKYLLLLLGGFQECED ATLALLARMGGQPAFTDLEVITNRPKGFTRFRSAVRVSIAISRMKFLVRR WHRVTGSVSININRDGFGLNQGAEKTDSFYHSSGGLELYGEPRHTTYRSR SDLDYIRSPLPFQNRYPGTPADFNPGSLACSQLQNYDPDRALTDYITRLE | 3173 |
3D view using mol* of 1254 (AA BP:380) | ||||||||||
![]() | ||||||||||
PDB file (1255) | BRAF | chr7 | 140494107 | - | AKAP9 | chr7 | 91641742 | + | MAALSGGGGGGAEPGQALFNGDMEPEAGAGAGAAASSAADPAIPEEVWNI KQMIKLTQEHIEALLDKFGGEHNPPSIYLEAYEEYTSKLDALQQREQQLL ESLGNGTDFSVSSSASMDTVTSSSSSSLSVLPSSLSVFQNPTDVARSNPK SPQKPIVRVFLPNKQRTVVPARCGVTVRDSLKKALMMRGLIPECCAVYRI QDGEKKPIGWDTDISWLTGEELHVEVLENVPLTTHNFVRKTFFTLAFCDF CRKLLFQGFRCQTCGYKFHQRCSTEVPLMCVNYDQLDLLFVSKFFEHHPI PQEEASLAETALTSGSSPSAPASDSIGPQILTSPSPSKSIPIPQPFRPAD EDHRNQFGQRDRSSSAPNVHINTIEPVNIDNDLRLQMEAQRICLSLVYST HVDQVREYMENEKDKALCSLKEELIFAQEEKIKELQKIHQLELQTMKTQE TGDEGKPLHLLIGKLQKAVSEECSYFLQTLCSVLGEYYTPALKCEVNAED KENSGDYISENEDPELQDYRYEVQDFQENMHTLLNKVTEEYNKLLVLQTR LSKIWGQQTDGMKLEFGEENLPKEETEFLSIHSQMTNLEDIDVNHKSKLS SLQDLEKTKLEEQVQELESLISSLQQQLKETEQNYEAEIHCLQKRLQAVS ESTVPPSLPVDSVVITESDAQRTMYPGSCVKKNIDGTIEFSGEFGVKEET NIVKLLEKQYQEQLEEEVAKVIVSMSIAFAQQTELSRISGGKENTASSKQ AHAVCQQEQHYFNEMKLSQDQIGFQTFETVDVKFKEEFKPLSKELGEHGK EILLSNSDPHDIPESKDCVLTISEEMFSKDKTFIVRQSIHDEISVSSMDA SRQLMLNEEQLEDMRQELVRQYQEHQQATELLRQAHMRQMERQREDQEQL QEEIKRLNRQLAQRSSIDNENLVSERERVLLEELEALKQLSLAGREKLCC ELRNSSTQTQNGNENQGEVEEQTFKEKELDRKPEDVPPEILSNERYALQK ANNRLLKILLEVVKTTAAVEETIGRHVLGILDRSSKSQSSASLIWRSEAE ASVKSCVHEEHTRVTDESIPSYSGSDMPRNDINMWSKVTEEGTELSQRLV RSGFAGTEIDPENEELMLNISSRLQAAVEKLLEAISETSSQLEHAKVTQT ELMRESFRQKQEATESLKCQEELRERLHEESRAREQLAVELSKAEGVIDG YADEKTLFERQIQEKTDIIDRLEQELLCASNRLQELEAEQQQIQEERELL SRQKEAMKAEAGPVEQQLLQETEKLMKEKLEVQCQAEKVRDDLQKQVKAL EIDVEEQVSRFIELEQEKNTELMDLRQQNQALEKQLEKMRKFLDEQAIDR EHERDVFQQEIQKLEQQLKVVPRFQPISEHQTREVEQLANHLKEKTDKCS ELLLSKEQLQRDIQERNEEIEKLEFRVRELEQALLVSADTFQKVEDRKHF GAVEAKPELSLEVQLQAERDAIDRKEKEITNLEEQLEQFREELENKNEEV QQLHMQLEIQKKESTTRLQELEQENKLFKDDMEKLGLAIKESDAMSTQDQ HVLFGKFAQIIQEKEVEIDQLNEQVTKLQQQLKITTDNKVIEEKNELIRD LETQIECLMSDQECVKRNREEEIEQLNEVIEKLQQELANIGQKTSMNAHS LSEEADSLKHQLDVVIAEKLALEQQVETANEEMTFMKNVLKETNFKMNQL TQELFSLKRERESVEKIQSIPENSVNVAIDHLSKDKPELEVVLTEDALKS LENQTYFKSFEENGKGSIINLETRLLQLESTVSAKDLELTQCYKQIKDMQ EQGQFETEMLQKKIVNLQKIVEEKVAAALVSQIQLEAVQEYAKFCQDNQT ISSEPERTNIQNLNQLREDELGSDISALTLRISELESQVVEMHTSLILEK EQVEIAEKNVLEKEKKLLELQKLLEGNEKKQREKEKKRSPQDVEVLKTTT ELFHSNEESGFFNELEALRAESVATKAELASYKEKAEKLQEELLVKETNM TSLQKDLSQVRDHLAEAKEKLSILEKEDETEVQESKKACMFEPLPIKLSK SIASQTDGTLKISSSNQTPQILVKNAGIQINLQSECSSEEVTEIISQFTE KIEKMQELHAAEILDMESRHISETETLKREHYVAVQLLKEECGTLKAVIQ CLRSKEGSSIPELAHSDAYQTREICSSDSGSDWGQGIYLTHSQGFDIASE GRGEESESATDSFPKKIKGLLRAVHNEGMQVLSLTESPYSDGEDHSIQQV SEPWLEERKAYINTISSLKDLITKMQLQREAEVYDSSQSHESFSDWRGEL LLALQQVFLEERSVLLAAFRTELTALGTTDAVGLLNCLEQRIQEQGVEYQ AAMECLQKADRRSLLSEIQALHAQMNGRKITLKREQESEKPSQELLEYNI QQKQSQMLEMQVELSSMKDRATELQEQLSSEKMVVAELKSELAQTKLELE TTLKAQHKHLKELEAFRLEVKDKTDEVHLLNDTLASEQKKSRELQWALEK EKAKLGRSEERDKEELEDLKFSLESQKQRNLQLNLLLEQQKQLLNESQQK IESQRMLYDAQLSEEQGRNLELQVLLESEKVRIREMSSTLDRERELHAQL QSSDGTGQSRPPLPSEDLLKELQKQLEEKHSRIVELLNETEKYKLDSLQT RQQMEKDRQVHRKTLQTEQEANTEGQKKMHELQSKVEDLQRQLEEKRQQV YKLDLEGQRLQGIMQEFQKQELEREEKRESRRILYQNLNEPTTWSLTSDR TRNWVLQQKIEGETKESNYAKLIEMNGGGTGCNHELEMIRQKLQCVASKL QVLPQKASERLQFETADDEDFIWVQENIDEIILQLQKLTGQQGEEPSLVS PSTSCGSLTERLLRQNAELTGHISQLTEEKNDLRNMVMKLEEQIRWYRQT GAGRDNSSRFSLNGGANIEAIIASEKEVWNREKLTLQKSLKRAEAEVYKL KAELRNDSLLQTLSPDSEHVTLKRIYGKYLRAESFRKALIYQKKYLLLLL GGFQECEDATLALLARMGGQPAFTDLEVITNRPKGFTRFRSAVRVSIAIS RMKFLVRRWHRVTGSVSININRDGFGLNQGAEKTDSFYHSSGGLELYGEP RHTTYRSRSDLDYIRSPLPFQNRYPGTPADFNPGSLACSQLQNYDPDRAL | 3181 |
Top |
pLDDT score distribution |
![]() * AlphaFold produces a per-residue confidence score (pLDDT) between 0 and 100. |
BRAF_pLDDT.png![]() |
AKAP9_pLDDT.png![]() |
![]() * AlphaFold produces a per-residue confidence score (pLDDT) between 0 and 100. |
Top |
Ramachandran Plot of Fusion Protein Structure |
![]() |
Fusion AA seq ID in FusionPDB and their Ramachandran plots |
BRAF_AKAP9_1251.png |
![]() |
BRAF_AKAP9_1254.png |
![]() |
Top |
Potential Active Site Information |
![]() |
Fusion AA seq ID in FusionPDB | Site score | Size | D score | Volume | Exposure | Enclosure | Contact | Phobic | Philic | Balance | Don/Acc | Residues |
1251 | 1.05828 | 216 | 1.12555 | 698.348 | 0.59322 | 0.684217 | 0.904956 | 1.439504 | 0.690123 | 2.085866 | 0.982167 | Chain A: 892,895,896,899,900,903,1158,1159,1162,11 63,1165,1166,1168,1169,1170,1172,1173,1174,1176,11 77,1180,2800,2801,2912,2913,2916,2917,2919,2920,29 21,2923,2924,2925,2927,2928,2993,2994,2996,2997,29 99,3000,3001 |
1254 | 1.098 | 196 | 1.111 | 325.164 | 0.372 | 0.836 | 1.15 | 1.242 | 1.013 | 1.226 | 0.595 | Chain A: 178,192,193,194,195,198,205,210,225,226,2 27,228,229,230,231,285,286,289,290,293,294,750,751 ,752,753,754,755,849,850,853,856,857,860 |
1255 | 1.049 | 294 | 1.113 | 998.816 | 0.645 | 0.68 | 0.825 | 0.914 | 0.72 | 1.269 | 1.514 | Chain A: 460,462,463,464,465,466,467,468,469,470,4 71,472,473,476,526,529,530,532,533,536,537,540,541 ,544,564,566,576,577,578,622,625,626,627,629,630,6 31,633,634,637,638,641,642,644,645,648,649,651,652 ,653,654,655,656,657,1625,1629,1632,1633,1636,1637 ,1640,1641,1650,1651,1652,1653,2573,2577,2580,2581 ,2584 |
Top |
Potentially Interacting Small Molecules through Virtual Screening |
![]() |
Fusion AA seq ID in FusionPDB | ZINC ID | DrugBank ID | Drug name | Docking score | Glide gscore |
Top |
![]() |
ZINC ID | DrugBank ID | Drug name | Drug type | SMILES | Drug group |
Top |
Biochemical Features of Small Molecules |
![]() |
ZINC ID | mol_MW | dipole | SASA | FOSA | FISA | PISA | WPSA | volume | donorHB | accptHB | IP | Human Oral Absorption | Percent Human Oral Absorption | Rule Of Five | Rule Of Three |
Top |
Drug Toxicity Information |
![]() |
ZINC ID | Smile | Surface Accessibility | Toxicity |
Top |
Fusion Protein-Protein Interaction |
![]() |
![]() |
Gene | PPI interactors |
AKAP9 | TACC3, FNBP1, TRIP10, PRKAR2A, KCNQ1, CLIC1, CALM2, CALM1, TUBGCP3, PKN1, Csnk1d, Csnk1e, CSNK1E, CSNK1D, PMS1, CDC5L, DISC1, TNIK, CEBPA, CCNE1, TSG101, gag-pol, CDK5RAP2, KDM1A, TDP2, PCNT, GSK3A, RASSF2, SUV39H2, PRKACA, PRKACB, MAGEA6, HNRNPM, SSX2, BLZF1, USO1, MAGED1, IKZF3, WAC, THAP1, PRDM14, USHBP1, C1orf94, SAMD3, SUZ12, RNF2, BMI1, ROPN1L, MAPRE1, CEP170, CCDC68, PRKAR2B, HERC2, GPC4, DYNLL1, HUWE1, FGFR1OP, THOC2, CEP170P1, Mapre1, Prkacb, Prkar2a, Prkar2b, Uso1, Fgfr1op, Cdk5rap2, PCGF1, NANOG, ATOH1, TPTE2, PDE4DIP, PRKACG, C1orf87, DNAJC10, BIRC6, TPM2, HEY1, PPIE, RBM14, PCM1, RPA2, KIF19, GTSE1, PARD6G, KLC4, CASK, PRC1, FMR1, CTBP1, RBM10, NDEL1, SF3B2, MED1, SLAIN1, FXR2, YWHAE, AKAP9, PKP2, MYO5A, DVL2, AGR2, KIAA1429, nsp13, VPS9D1, THOC1, RSRC2, SNRPB, GLIS2, BEX2, CCDC146, ABI2, FAM46B, SNF8, CCDC116, SCNM1, TLX3, SSX5, SSX3, LMO1, FAM90A1, TCEANC, CTNNA3, HDDC3, PTPN6, HNRNPC, HMGA1, RFC5, HSPD1, DHX9, HNRNPCL2, VDAC2, NONO, SMC3, nsp16, ORF6, TULP3, CIT, KIF14, MTX2, nsp13ab, HDAC1, ACBD5, AP2B1, CAMSAP2, CEP135, DCTN2, GOLGA2, IMPDH2, KRT19, KRT8, LATS1, MAPRE3, NDC80, PFN1, PXN, SEPT10, STIL, LOC338797, CTCFL, EFCAB1, SOGA1, OR10H1, STK11, PIGF, SYCE1, WHAMMP3, COQ3, RAMP1, ABCF3, RNF145, DDX55, DYNLL2, SLU7, BRK1, ZBTB44, FTSJ3, CCDC71, VDR, BNIP1, LINC00346, CEP57, ZNF252P-AS1, CARD9, NDUFAF1, ROPN1, NOLC1, |
BRAF | YWHAB, YWHAG, YWHAQ, YWHAZ, SFN, HRAS, AKT1, MAPK3, RAP1GAP, RAF1, MRAS, RAP1A, PAK2, TERF1, CCDC88A, NEDD4L, Nedd4, MAP2K1, RNF149, KSR1, BRAP, PRKCE, RPS6KB2, HSP90AA1, BRAF, YWHAE, HSPA5, MAP2K2, HSPA1A, HSPA8, YWHAH, HSPA9, ARAF, CDC37, HSP90AB1, PHKB, LIMK1, IQGAP1, MAPK1, BAD, LIPF, MUS81, Vps4b, FBXW7, FGFR2, BRCA2, VHL, FNTA, HDAC2, PIK3CA, EGFR, PTEN, FNIP1, FNIP2, RAB3GAP1, KRAS, KIAA0141, FKBPL, ARMCX3, KCNC4, RPTOR, CYLD, NRAS, HSPA4, DNAJB6, PDCD11, PIP5K1A, DNAJC15, VANGL1, DNAJC11, FKBP5, HSPA4L, HSP90B1, GNAI2, DNAJC13, GNAS, PPP2CB, HSD11B2, DNAJB11, PLD2, RAP1B, WDR6, CPNE3, MYOF, COPA, UBLCP1, PPP1CA, RAD50, PIP4K2C, PHB, VIM, PGAM1, DNAJA1, MAP2K7, SPRY2, ALDOA, AP2B1, ATP5A1, SSB, IGF1R, JUP, PPP6C, PARP1, HSPB1, NME2, PRDX2, CCT7, RAB1A, FARSA, FASN, EPRS, TRAF2, REST, KIAA1429, NANOG, ITCH, SMURF2, WWP1, WWP2, PPP2CA, PPP2R2A, AURKA, LATS2, MAP2K3, MAP2K6, RASSF1, STK11, TERT, PEBP1, CRBN, FAR1, PSMC4, UBA52, UBB, UBC, RPS27A, HSPA6, HSP90AB3P, DSP, ATAD3A, ATAD3B, P4HB, SDF2L1, SLC25A22, SPTBN4, TMEM33, CTSB, NCL, HPX, TXNDC12, SLC25A11, NDUFA4, CTSV, FBP1, HSD17B3, ZNF189, ZNF510, KIF14, SRC, TRAP1, JTB, S100P, USP28, |
![]() |
Gene | STRING network |
BRAF | ![]() |
AKAP9 | ![]() |
![]() |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
![]() |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
Related Drugs to BRAF-AKAP9 |
![]() (Manual curation of PubMed, 04-30-2022 + MyCancerGenome) |
Hgene | Tgene | Drug | Source | PMID |
Top |
Related Diseases to BRAF-AKAP9 |
![]() (Manual curation of PubMed, 04-30-2022 + MyCancerGenome) |
Hgene | Tgene | Disease | Source | PMID |
BRAF | AKAP9 | Thyroid Gland Papillary Carcinoma | MyCancerGenome | |
BRAF | AKAP9 | Low-Grade Glioma | MyCancerGenome | |
BRAF | AKAP9 | Nos | MyCancerGenome | |
BRAF | AKAP9 | Pancreatic Adenocarcinoma | MyCancerGenome | |
BRAF | AKAP9 | Pilocytic Astrocytoma | MyCancerGenome | |
BRAF | AKAP9 | Astrocytoma | MyCancerGenome |
![]() (DisGeNet 4.0) |
Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
Hgene | BRAF | C0025202 | melanoma | 24 | CGI;CTD_human;UNIPROT |
Hgene | BRAF | C1275081 | Cardio-facio-cutaneous syndrome | 14 | CLINGEN;CTD_human;GENOMICS_ENGLAND;ORPHANET;UNIPROT |
Hgene | BRAF | C0009402 | Colorectal Carcinoma | 8 | CTD_human;UNIPROT |
Hgene | BRAF | C0028326 | Noonan Syndrome | 8 | CLINGEN;CTD_human;GENOMICS_ENGLAND;ORPHANET |
Hgene | BRAF | C0238463 | Papillary thyroid carcinoma | 8 | CTD_human;ORPHANET |
Hgene | BRAF | C0040136 | Thyroid Neoplasm | 6 | CGI;CTD_human |
Hgene | BRAF | C0151468 | Thyroid Gland Follicular Adenoma | 6 | CTD_human |
Hgene | BRAF | C0175704 | LEOPARD Syndrome | 6 | CLINGEN;GENOMICS_ENGLAND |
Hgene | BRAF | C0549473 | Thyroid carcinoma | 6 | CGI;CTD_human |
Hgene | BRAF | C3150970 | NOONAN SYNDROME 7 | 5 | CTD_human;GENOMICS_ENGLAND;UNIPROT |
Hgene | BRAF | C0009404 | Colorectal Neoplasms | 4 | CTD_human |
Hgene | BRAF | C3150971 | LEOPARD SYNDROME 3 | 4 | CTD_human;GENOMICS_ENGLAND;UNIPROT |
Hgene | BRAF | C1519086 | Pilomyxoid astrocytoma | 3 | ORPHANET |
Hgene | BRAF | C0004565 | Melanoma, B16 | 2 | CTD_human |
Hgene | BRAF | C0009075 | Melanoma, Cloudman S91 | 2 | CTD_human |
Hgene | BRAF | C0018598 | Melanoma, Harding-Passey | 2 | CTD_human |
Hgene | BRAF | C0023443 | Hairy Cell Leukemia | 2 | CGI;ORPHANET |
Hgene | BRAF | C0025205 | Melanoma, Experimental | 2 | CTD_human |
Hgene | BRAF | C0033578 | Prostatic Neoplasms | 2 | CTD_human |
Hgene | BRAF | C0152013 | Adenocarcinoma of lung (disorder) | 2 | CGI;CTD_human |
Hgene | BRAF | C0376358 | Malignant neoplasm of prostate | 2 | CTD_human |
Hgene | BRAF | C0587248 | Costello syndrome (disorder) | 2 | CLINGEN;CTD_human |
Hgene | BRAF | C3501843 | Nonmedullary Thyroid Carcinoma | 2 | CTD_human |
Hgene | BRAF | C3501844 | Familial Nonmedullary Thyroid Cancer | 2 | CTD_human |
Hgene | BRAF | C0002448 | Ameloblastoma | 1 | CTD_human |
Hgene | BRAF | C0004114 | Astrocytoma | 1 | CTD_human |
Hgene | BRAF | C0010276 | Craniopharyngioma | 1 | CTD_human;ORPHANET |
Hgene | BRAF | C0011860 | Diabetes Mellitus, Non-Insulin-Dependent | 1 | CTD_human |
Hgene | BRAF | C0017638 | Glioma | 1 | CGI;CTD_human |
Hgene | BRAF | C0019621 | Histiocytosis, Langerhans-Cell | 1 | CGI;ORPHANET |
Hgene | BRAF | C0022665 | Kidney Neoplasm | 1 | CTD_human |
Hgene | BRAF | C0023903 | Liver neoplasms | 1 | CTD_human |
Hgene | BRAF | C0024232 | Lymphatic Metastasis | 1 | CTD_human |
Hgene | BRAF | C0024694 | Mandibular Neoplasms | 1 | CTD_human |
Hgene | BRAF | C0027659 | Neoplasms, Experimental | 1 | CTD_human |
Hgene | BRAF | C0027962 | Melanocytic nevus | 1 | GENOMICS_ENGLAND |
Hgene | BRAF | C0036920 | Sezary Syndrome | 1 | CTD_human |
Hgene | BRAF | C0041409 | Turner Syndrome, Male | 1 | CTD_human |
Hgene | BRAF | C0079773 | Lymphoma, T-Cell, Cutaneous | 1 | CTD_human |
Hgene | BRAF | C0205768 | Subependymal Giant Cell Astrocytoma | 1 | CTD_human |
Hgene | BRAF | C0206686 | Adrenocortical carcinoma | 1 | CTD_human |
Hgene | BRAF | C0206754 | Neuroendocrine Tumors | 1 | CTD_human |
Hgene | BRAF | C0259783 | mixed gliomas | 1 | CTD_human |
Hgene | BRAF | C0278875 | Adult Craniopharyngioma | 1 | CTD_human |
Hgene | BRAF | C0280783 | Juvenile Pilocytic Astrocytoma | 1 | CTD_human |
Hgene | BRAF | C0280785 | Diffuse Astrocytoma | 1 | CTD_human |
Hgene | BRAF | C0334579 | Anaplastic astrocytoma | 1 | CGI;CTD_human |
Hgene | BRAF | C0334580 | Protoplasmic astrocytoma | 1 | CTD_human |
Hgene | BRAF | C0334581 | Gemistocytic astrocytoma | 1 | CTD_human |
Hgene | BRAF | C0334582 | Fibrillary Astrocytoma | 1 | CTD_human |
Hgene | BRAF | C0334583 | Pilocytic Astrocytoma | 1 | CGI;CTD_human |
Hgene | BRAF | C0338070 | Childhood Cerebral Astrocytoma | 1 | CTD_human |
Hgene | BRAF | C0345904 | Malignant neoplasm of liver | 1 | CTD_human |
Hgene | BRAF | C0376407 | Granulomatous Slack Skin | 1 | CTD_human |
Hgene | BRAF | C0406803 | Syringocystadenoma Papilliferum | 1 | GENOMICS_ENGLAND |
Hgene | BRAF | C0431128 | Papillary craniopharyngioma | 1 | CTD_human |
Hgene | BRAF | C0431129 | Adamantinous Craniopharyngioma | 1 | CTD_human |
Hgene | BRAF | C0547065 | Mixed oligoastrocytoma | 1 | CTD_human |
Hgene | BRAF | C0555198 | Malignant Glioma | 1 | CTD_human |
Hgene | BRAF | C0596263 | Carcinogenesis | 1 | CTD_human |
Hgene | BRAF | C0684249 | Carcinoma of lung | 1 | CGI;UNIPROT |
Hgene | BRAF | C0740457 | Malignant neoplasm of kidney | 1 | CTD_human |
Hgene | BRAF | C0750935 | Cerebral Astrocytoma | 1 | CTD_human |
Hgene | BRAF | C0750936 | Intracranial Astrocytoma | 1 | CTD_human |
Hgene | BRAF | C0751061 | Craniopharyngioma, Child | 1 | CTD_human |
Hgene | BRAF | C0920269 | Microsatellite Instability | 1 | CTD_human |
Hgene | BRAF | C1527404 | Female Pseudo-Turner Syndrome | 1 | CTD_human |
Hgene | BRAF | C1704230 | Grade I Astrocytoma | 1 | CTD_human |
Hgene | BRAF | C1721098 | Replication Error Phenotype | 1 | CTD_human |
Hgene | BRAF | C2239176 | Liver carcinoma | 1 | CTD_human |
Hgene | BRAF | C4551484 | Leopard Syndrome 1 | 1 | GENOMICS_ENGLAND |
Hgene | BRAF | C4551602 | Noonan Syndrome 1 | 1 | CTD_human |
Hgene | BRAF | C4721532 | Lymphoma, Non-Hodgkin, Familial | 1 | UNIPROT |
Hgene | BRAF | C4733333 | familial non-medullary thyroid cancer | 1 | GENOMICS_ENGLAND |
Tgene | AKAP9 | C2678483 | Long Qt Syndrome 11 | 4 | CLINGEN;CTD_human;GENOMICS_ENGLAND;UNIPROT |
Tgene | AKAP9 | C0035828 | Romano-Ward Syndrome | 1 | ORPHANET |
Tgene | AKAP9 | C0037274 | Dermatologic disorders | 1 | CTD_human |
Tgene | AKAP9 | C0274861 | Arsenic Poisoning, Inorganic | 1 | CTD_human |
Tgene | AKAP9 | C0274862 | Nervous System, Organic Arsenic Poisoning | 1 | CTD_human |
Tgene | AKAP9 | C0311375 | Arsenic Poisoning | 1 | CTD_human |
Tgene | AKAP9 | C0751851 | Arsenic Encephalopathy | 1 | CTD_human |
Tgene | AKAP9 | C0751852 | Arsenic Induced Polyneuropathy | 1 | CTD_human |
Tgene | AKAP9 | C1142166 | Brugada Syndrome (disorder) | 1 | ORPHANET |